CAS NO: | 78123-71-4 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | DAMGO is aμ-opioid receptor(μ-OPR) selective agonist with aKdof 3.46 nM for native μ-OPR[1]. | ||||||||||||||||
IC50& Target | Kd: 3.46±0.84 nM (native μ-OPR)[1] | ||||||||||||||||
体外研究 (In Vitro) | DAMGO (1-10 μM) significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival, but does not down-regulate CXCR4 protein expression[2]. | ||||||||||||||||
体内研究 (In Vivo) | DAMGO (i.v., 0.5-2 mg/kg) can produce significant anti-injury effects on injured paws of male Sprague-Dawley rats weighing 200-225 g in a dose-dependent manner, producing an effective and long-lasting analgesic effect[4]. | ||||||||||||||||
分子量 | 513.59 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C26H35N5O6 | ||||||||||||||||
CAS 号 | 78123-71-4 | ||||||||||||||||
Sequence | Tyr-{d-Ala}-Gly-{Me-Phe}-Gly-ol | ||||||||||||||||
Sequence Shortening | Y-{d-Ala}-G-{Me-Phe}-G-ol | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : ≥ 100 mg/mL(194.71 mM) DMSO : 33.33 mg/mL(64.90 mM;Need ultrasonic) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|